WIENER MEDIZINISCHE WOCHENSCHRIFT, published by SPRINGER WIEN, stands as a pivotal journal in the field of general medicine, with a significant history dating back to its inception in 1946. With its ISSN 0043-5341 and E-ISSN 1563-258X, this journal seeks to bridge the gap between research and clinical practice, offering a platform for the dissemination of vital medical knowledge and innovations. While currently placed in the Q3 quartile of the medicine category and ranking #210 out of 636 in Scopus, it boasts a 67th percentile ranking, underscoring its impact and relevance among practitioners and researchers alike. Although not an open-access journal, its accessibility through institutional subscriptions ensures that a wide audience can engage with its comprehensive articles that cover myriad topics in medicine. As the field continuously evolves, WIENER MEDIZINISCHE WOCHENSCHRIFT is committed to advancing medical understanding and fostering discussions that resonate within Austria and beyond, making it an essential resource for healthcare professionals, academia, and students seeking to stay abreast of current medical advancements.

HEALTH TECHNOLOGY ASSESSMENT is a prestigious open-access journal published by the NIHR Journals Library, focusing on advancing the science of health technology assessment through robust research and critical analysis in the fields of Health Policy and Medicine. Since its inception in 2001, this journal has fostered a multidisciplinary approach to evaluating health technologies, offering invaluable insights to researchers, healthcare professionals, and policymakers. With an impressive Q1 ranking in both Health Policy and Medicine (miscellaneous) for 2023, it stands at the forefront of academic discourse, reflecting a high-impact factor and an esteemed reputation within its respective categories. The journal not only publishes original research articles, but also reviews and case studies that illuminate the complexities of health technology in real-world applications. Established and based in the United Kingdom, HEALTH TECHNOLOGY ASSESSMENT strives to encourage evidence-based decision-making, making it an essential resource for anyone committed to enhancing healthcare outcomes through innovative technology assessments.

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

EXPERT OPINION ON EMERGING DRUGS, published by Taylor & Francis Ltd, stands at the forefront of the pharmacological sciences, focusing on the rapid development and evaluation of innovative therapeutic agents. With an impressive impact factor that reflects its contributions to the field, this journal is indexed under ISSN 1472-8214 and E-ISSN 1744-7623. The journal has consistently attained high recognition, currently holding a Q2 ranking in Pharmacology and a Q1 ranking in Pharmacology (medical) as of 2023, which places it within the top tiers of scholarly publications. Covering a broad range of topics related to emerging pharmaceuticals, it aims to bridge the gap between research and clinical practice by providing critical reviews, expert opinions, and insightful analyses. Based in the United Kingdom and actively published since 2000, the journal seeks to inform and inspire researchers, professionals, and students alike, offering a platform to foster collaboration and insight within the ever-evolving domain of drug development and pharmacotherapy.

ANNALS ACADEMY OF MEDICINE SINGAPORE is a reputable journal dedicated to the field of medicine, published by the Academy of Medicine, Singapore. With an E-ISSN of 2972-4066, this journal has been an influential platform since its inception in 1973, aiming to disseminate high-quality research and clinical findings pertinent to both local and international audiences. Currently ranked in the Q3 quartile in Medicine (miscellaneous), it holds a commendable 83rd percentile in Scopus rankings, indicating its significant academic contribution within the competitive landscape of medical literature. Although the journal operates on a traditional subscription-based model, it continues to provide access to critical insights that serve not only researchers but also healthcare professionals and students engaged in the ever-evolving medical sector. As it approaches its comprehensive publication mark in 2024, ANNALS will continue to focus on enhancing global healthcare discourse, making it an invaluable resource for those committed to advancing medical knowledge and practice.

The Electronic Journal of General Medicine is a distinguished open-access publication dedicated to advancing the field of general medicine through the dissemination of high-quality research and innovative practices. Published by MODESTUM LTD in the United Kingdom, this journal has been a pivotal platform for medical professionals and researchers since 2018, with an impressive Scopus ranking of #145 out of 636 in the Medicine category, placing it in the 77th percentile. It holds a Q3 quartile ranking in the 2023 medicine (miscellaneous) category, underscoring its relevance and contribution to the academic community. The journal focuses on a wide range of topics within general medicine, inviting original research articles, reviews, and case studies that address contemporary medical challenges. By providing a straightforward publication avenue, the Electronic Journal of General Medicine fosters knowledge exchange and stimulates scholarly dialogue, making it an essential resource for researchers, healthcare professionals, and students seeking to stay informed on the latest developments in the field.

Journal of Health Economics and Outcomes Research, published by COLUMBIA DATA ANALYTICS, LLC, serves as a vital resource in the field of health policy and public health, providing researchers, professionals, and students with open access to pioneering studies since its inception in 2013. With its ISSN and E-ISSN both listed as 2327-2236, this journal aims to disseminate high-quality research that evaluates healthcare efficiency and outcomes. Situated in the United States, at 145 Hudson St., Suite 205, New York, NJ 10013, it has made significant strides in its category quartiles within the 2023 rankings, achieving Q2 status in both Health Policy and Public Health, Environmental and Occupational Health. Furthermore, it maintains respectable Scopus rankings, with a percentile of 51st in health policy and 49th in public health. By bridging gaps in health economics and policy discourse, the journal stands as an indispensable platform for advancing knowledge and fostering innovation in health services research.

EXPERT OPINION ON BIOLOGICAL THERAPY, published by Taylor & Francis Ltd, is a prestigious journal that has been a cornerstone in the fields of Clinical Biochemistry, Drug Discovery, and Pharmacology since its inception in 2001. With an impressive impact factor reflecting Q1 status across its categories in 2023, this journal is ranked among the top in both the pharmacology and biochemistry domains, featuring in the 81st and 77th percentiles respectively. This makes it an essential resource for researchers, professionals, and students who are keen on staying at the forefront of biological therapy advancements. The journal encompasses a broad yet focused scope, providing valuable insights into innovative therapeutic strategies and drug development methodologies. Researchers benefit from the rigorous peer-review process and the opportunity to disseminate their findings to a global audience, without the constraints of open access, ensuring the integrity and prestige of published work. As it converges towards 2024, EXPERT OPINION ON BIOLOGICAL THERAPY remains an influential platform for fostering collaboration and discussion in the evolutionary landscape of biological therapies.

DRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.

JAMA Internal Medicine is a premier scholarly journal published by the American Medical Association, renowned for its rigorous peer-review process and commitment to advancing the field of internal medicine. With an impressive impact factor that positions it in the upper echelon of medical journals, specifically ranked at Q1 in Internal Medicine and holding a remarkable Scopus rank of #2 out of 167, the journal provides a vital platform for original research, reviews, and enlightening discussions that shape clinical practices and policies. As an accessible repository of cutting-edge findings and comprehensive analyses, JAMA Internal Medicine offers both subscription and open access options, ensuring that the latest developments in medicine are available to clinicians, researchers, and the academic community at large. With its focus spanning from 2013 to 2024 and its dedication to high-quality scholarship, the journal serves as an essential resource for those seeking to enhance their understanding of the complexities of internal medicine and improve patient care.